CA3018932C - Pharmaceutical combinations for the treatment of cancer - Google Patents

Pharmaceutical combinations for the treatment of cancer Download PDF

Info

Publication number
CA3018932C
CA3018932C CA3018932A CA3018932A CA3018932C CA 3018932 C CA3018932 C CA 3018932C CA 3018932 A CA3018932 A CA 3018932A CA 3018932 A CA3018932 A CA 3018932A CA 3018932 C CA3018932 C CA 3018932C
Authority
CA
Canada
Prior art keywords
treatment
cancer
pharmaceutical combinations
inhibitor
combination therapies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3018932A
Other languages
English (en)
French (fr)
Other versions
CA3018932A1 (en
Inventor
Richard Klinghoffer
Joyoti DEY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Presage Biosciences Inc
Original Assignee
Presage Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Presage Biosciences Inc filed Critical Presage Biosciences Inc
Priority to CA3103604A priority Critical patent/CA3103604C/en
Publication of CA3018932A1 publication Critical patent/CA3018932A1/en
Application granted granted Critical
Publication of CA3018932C publication Critical patent/CA3018932C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3018932A 2016-03-28 2017-03-28 Pharmaceutical combinations for the treatment of cancer Active CA3018932C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3103604A CA3103604C (en) 2016-03-28 2017-03-28 Pharmaceutical combinations for the treatment of cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662314356P 2016-03-28 2016-03-28
US62/314,356 2016-03-28
PCT/US2017/024618 WO2017172826A1 (en) 2016-03-28 2017-03-28 Pharmaceutical combinations for the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3103604A Division CA3103604C (en) 2016-03-28 2017-03-28 Pharmaceutical combinations for the treatment of cancer

Publications (2)

Publication Number Publication Date
CA3018932A1 CA3018932A1 (en) 2017-10-05
CA3018932C true CA3018932C (en) 2021-10-26

Family

ID=59966407

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3018932A Active CA3018932C (en) 2016-03-28 2017-03-28 Pharmaceutical combinations for the treatment of cancer
CA3103604A Active CA3103604C (en) 2016-03-28 2017-03-28 Pharmaceutical combinations for the treatment of cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3103604A Active CA3103604C (en) 2016-03-28 2017-03-28 Pharmaceutical combinations for the treatment of cancer

Country Status (13)

Country Link
US (5) US11135198B2 (enExample)
EP (1) EP3436002B1 (enExample)
JP (3) JP7114478B2 (enExample)
KR (5) KR102494039B1 (enExample)
CN (1) CN109689047B (enExample)
AU (4) AU2017241914B2 (enExample)
CA (2) CA3018932C (enExample)
IL (3) IL295472B2 (enExample)
MX (3) MX2018011666A (enExample)
NZ (2) NZ747404A (enExample)
RU (1) RU2726367C2 (enExample)
WO (1) WO2017172826A1 (enExample)
ZA (2) ZA201806819B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2624981T3 (es) 2011-07-01 2017-07-18 Dana-Farber Cancer Institute, Inc. Descubrimiento de una mutación somática en el gen MYD88 en linfoma linfoplasmocitario
AU2014361798B2 (en) 2013-12-13 2020-06-11 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
KR102494039B1 (ko) * 2016-03-28 2023-01-30 프레시지 바이오싸이언시스, 인크. 암 치료를 위한 제약학적 조합물
WO2019089641A1 (en) * 2017-10-31 2019-05-09 Eisai R&D Management Co., Ltd. Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from bcl2 inhibitors, bcl2/bclxl inhibitors, and bclxl inhibitors and methods of use
CN108186642B (zh) * 2018-01-11 2019-11-08 广西师范大学 一种协同起作用治疗肺癌的药物组合物
CN108261414B (zh) * 2018-01-11 2019-09-06 广西师范大学 一种治疗肺癌的药物组合物
JP2021534114A (ja) * 2018-08-14 2021-12-09 エムイーアイ ファーマ，インク． 併用療法
WO2020092615A1 (en) * 2018-11-01 2020-05-07 Oregon Health & Science University Treatments for venetoclax-resistant and venetoclax-sensitive acute myeloid leukemia
EP3952861A4 (en) 2019-04-11 2023-01-11 MEI Pharma, Inc. VORUCICLIB POLYMORPHS AND PROCESSES FOR THEIR PRODUCTION AND USE
EP4041239B1 (en) * 2019-10-08 2025-09-03 Dana-Farber Cancer Institute, Inc. A pyrrazolopyrimidine derivative as a hck inhibitor for use in therapy, in particular myd88 mutated diseases
CN115666574A (zh) * 2020-05-07 2023-01-31 里科瑞尔姆Ip控股有限责任公司 组合
CN117043159A (zh) * 2020-11-19 2023-11-10 梅制药公司 Kras突变型癌症的治疗
JP2024500288A (ja) * 2020-11-19 2024-01-09 メイ ファーマ，インク． Ｋｒａｓ変異癌の治療
CN113018357A (zh) * 2021-02-08 2021-06-25 湖南农业大学 茶多酚和帕博西尼联合在制备治疗乳腺癌的制剂中的用途
WO2022217133A1 (en) * 2021-04-10 2022-10-13 Mei Pharma, Inc. Voruciclib dosing regimens and methods of treatment including the same
WO2024239512A1 (zh) * 2023-05-22 2024-11-28 劲方医药科技(上海)有限公司 药物组合及其在治疗癌症中的用途
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2219867A1 (en) * 1997-10-31 1999-04-30 Jiangping Wu The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
AR031130A1 (es) 2000-09-20 2003-09-10 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
US7271193B2 (en) 2002-07-08 2007-09-18 Nicholas Piramal India, Ltd. Inhibitors of cyclin-dependent kinases and their use
TWI331034B (en) 2002-07-08 2010-10-01 Piramal Life Sciences Ltd Inhibitors of cyclin-dependent kinases and their use
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US7642260B2 (en) 2003-11-13 2010-01-05 Abbott Laboratories, Inc. Apoptosis promoters
US7767684B2 (en) 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
CN101006065B (zh) 2004-06-17 2012-07-11 英菲尼蒂发现公司 抑制bcl蛋白与结合伴侣的相互作用的化合物和方法
US7842815B2 (en) 2004-06-17 2010-11-30 Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
TWI337608B (en) 2005-05-12 2011-02-21 Abbott Lab Apoptosis promoters
EP1888543B1 (en) 2005-05-24 2012-08-01 Abbott Laboratories Apoptosis promoters
US20090142337A1 (en) * 2006-05-08 2009-06-04 Astex Therapeutics Limited Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment
EP2046738B1 (en) 2006-06-21 2014-06-11 Piramal Enterprises Limited Enantiomerically pure flavone derivatives for the treatment of proliferative disorders and processes for their preparation
US8822526B2 (en) * 2007-05-15 2014-09-02 Piramal Enterprises Limited Synergistic pharmaceutical combination for the treatment of cancer
US9259399B2 (en) * 2007-11-07 2016-02-16 Cornell University Targeting CDK4 and CDK6 in cancer therapy
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
CN102325531B (zh) 2008-12-19 2014-04-02 健泰科生物技术公司 化合物和使用方法
TWI535712B (zh) 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
MX2013005661A (es) * 2010-11-19 2013-09-13 Piramal Entpr Ltd Combinacion farmaceutica de paclitaxel y un inhibidor cdk (quinasa dependiente de ciclina).
TW201300105A (zh) * 2011-05-31 2013-01-01 Piramal Life Sciences Ltd 治療頭頸鱗狀細胞癌之相乘藥物組合物
WO2014018668A2 (en) * 2012-07-24 2014-01-30 Genoa Pharmaceuticals, Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US9241941B2 (en) * 2012-09-20 2016-01-26 Memorial Sloan-Kettering Cancer Center Methods for treatment of lymphomas with mutations in cell cycle genes
JP6347793B2 (ja) 2013-01-16 2018-06-27 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン Ｂｃｌ−２／Ｂｃｌ−ｘＬ阻害薬およびそれを使用した治療方法
KR20150131276A (ko) * 2013-03-14 2015-11-24 오닉스 세라퓨틱스, 인크. 디펩타이드 및 트리펩타이드 에폭시 케톤 프로테이스 억제제
AU2014296032A1 (en) * 2013-07-31 2016-03-17 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
US10314842B2 (en) 2013-12-02 2019-06-11 Cornell University Methods for treating B cell proliferative disorders
ES2818110T3 (es) * 2014-02-28 2021-04-09 Merck Sharp & Dohme Tratamiento del cáncer con una combinación que comprende dinaciclib
WO2015181737A1 (en) * 2014-05-28 2015-12-03 Piramal Enterprises Limited Pharmaceutical combination for the treatment of cancer
US20170231986A1 (en) 2014-08-11 2017-08-17 Acerta Pharma B.V. Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor
US9637488B2 (en) * 2015-01-29 2017-05-02 Fuqiang Ruan Heterocyclic compounds as inhibitors of class I PI3KS
KR102494039B1 (ko) * 2016-03-28 2023-01-30 프레시지 바이오싸이언시스, 인크. 암 치료를 위한 제약학적 조합물

Also Published As

Publication number Publication date
US11135198B2 (en) 2021-10-05
KR102545392B1 (ko) 2023-06-20
IL295472B1 (en) 2024-06-01
EP3436002B1 (en) 2025-11-05
US20210283104A1 (en) 2021-09-16
IL261824B2 (en) 2023-02-01
ZA201806819B (en) 2022-03-30
JP2024038227A (ja) 2024-03-19
US20250221961A1 (en) 2025-07-10
KR20230021155A (ko) 2023-02-13
KR20230093360A (ko) 2023-06-27
KR102599512B1 (ko) 2023-11-07
AU2020201247A1 (en) 2020-03-12
US12171744B2 (en) 2024-12-24
AU2024200194A1 (en) 2024-02-01
MX2018011666A (es) 2019-07-08
IL312398A (en) 2024-06-01
CA3103604A1 (en) 2017-10-05
RU2020121147A (ru) 2021-11-03
RU2018137687A3 (enExample) 2020-04-29
KR102494039B1 (ko) 2023-01-30
RU2018137687A (ru) 2020-04-29
US20200383948A1 (en) 2020-12-10
RU2726367C2 (ru) 2020-07-13
NZ757763A (en) 2025-07-25
KR20230156443A (ko) 2023-11-14
KR102275758B1 (ko) 2021-07-12
JP7416872B2 (ja) 2024-01-17
KR20210088016A (ko) 2021-07-13
ZA202107579B (en) 2025-03-26
AU2020201247B2 (en) 2021-08-26
EP3436002A4 (en) 2019-12-04
JP7114478B2 (ja) 2022-08-08
IL295472A (en) 2022-10-01
CN109689047B (zh) 2025-03-21
AU2017241914A1 (en) 2018-11-08
MX2022011750A (es) 2022-10-18
IL295472B2 (en) 2024-10-01
NZ747404A (en) 2020-03-27
JP2022141916A (ja) 2022-09-29
CN109689047A (zh) 2019-04-26
CA3018932A1 (en) 2017-10-05
AU2021273532B2 (en) 2024-02-01
US20190275004A1 (en) 2019-09-12
KR20190039878A (ko) 2019-04-16
IL261824B (en) 2022-10-01
AU2021273532A1 (en) 2021-12-16
WO2017172826A1 (en) 2017-10-05
EP3436002A1 (en) 2019-02-06
JP2019514854A (ja) 2019-06-06
US20220023261A1 (en) 2022-01-27
US12121508B2 (en) 2024-10-22
MX2022002318A (es) 2022-04-06
IL261824A (en) 2018-10-31
CA3103604C (en) 2023-09-26
AU2017241914B2 (en) 2020-02-27

Similar Documents

Publication Publication Date Title
ZA202107579B (en) Pharmaceutical combinations for the treatment of cancer
CA2983481A1 (en) Janus kinase inhibitor
WO2016133903A3 (en) Combination therapy for cancer treatment
NZ779654A (en) Tetrahydro-1h-pyrido[3,4-b]indole anti-estrogenic drugs
WO2017075629A3 (en) Wee 1 kinase inhibitors and methods of making and using the same
TN2017000511A1 (en) New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them.
GEP20207161B (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
PH12017500367A1 (en) Compounds that inhibit mcl-1 protein
UA117976C2 (uk) Сполуки амінопіримідинілу як інгібітори jak
GEP20217211B (en) Substituted carbonucleoside derivatives useful as anticancer agents
PH12019550224A1 (en) Antitumoral compounds
WO2018086591A8 (zh) 吡啶胺取代的杂三环化合物、其制法与医药上的用途
GEP20207160B (en) New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
SA519402288B1 (ar) مركب بيريميدين واستخداماته الصيدلانية
MY197626A (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
WO2015160975A3 (en) Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer
PH12019501022A1 (en) Pyrazolopyrimidine compounds and methods of use thereof
WO2019204505A3 (en) K-ras modulators with a vinyl sulfonamide moiety
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
MX2021003686A (es) Medicamento para el tratamiento de la tos cronica.
WO2018125880A8 (en) Nrf2 activator
EA202091169A1 (ru) Применяемые в качестве ингибиторов iap миметики smac и их применение
NZ732704A (en) Quinoline carboxamides for use in the treatment of leukemia
WO2018086589A8 (zh) 1,5,7-三取代的异喹啉衍生物、其制法与医药上的用途
MX2017002544A (es) Derivados de isoquinolinona utiles en el tratamiento contra el cancer.

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180924